As of June 30, 2026, MedRobot's analysis of publicly disclosed procurement awards from public hospitals across mainland China (excluding Hong Kong, Macau and Taiwan) shows that 44 orthopedic surgical robot systems were awarded during the first half of 2026. These projects involved 16 manufacturers, with a total disclosed procurement value of approximately RMB 258 million.

Compared with the first half of 2025, when 34 systems from 11 manufacturers were awarded, the market expanded by 10 additional systems, representing a 29.4% year-over-year increase, while the number of participating manufacturers also grew significantly.

Behind this expansion, however, an even more noteworthy trend is the ongoing differentiation among market players. TINAVI Medical maintained its procurement volume but experienced a decline in market share as overall market participation increased. Tuodao Medical doubled its awarded volume to become the second-largest domestic supplier, while leasing-based procurement emerged for the first time at meaningful scale.

Based on publicly available procurement data, this report examines four key aspects of China's orthopedic surgical robot market during the first half of 2026:

● Overall market landscape

● Evolution of the competitive landscape

● Pricing trends and procurement models

● Hospital purchasing behavior

Note: This report is manually compiled by MedRobot based solely on publicly available procurement announcements from mainland China's public hospitals. Only publicly disclosed projects are included in the analysis.

01 Overall Market Landscape:

Expanding Market Volume, Declining Average Selling Prices and Growing Vendor Participation

Table 1. Comparison of China's Orthopedic Surgical Robot Market: H1 2025 vs. H1 2026

During the first half of 2026, China's public hospitals announced procurement awards for 44 orthopedic surgical robot systems, an increase of 10 systems compared with the same period in 2025, representing 29.4% year-over-year growth.

The orthopedic surgical robotics market in China continues to be overwhelmingly dominated by domestic manufacturers. During the reporting period, Chinese brands accounted for approximately 93% of all awarded systems, while imported brands represented only three systems.

• Two market indicators deserve particular attention.

Diverging Trends Between Procurement Volume and Procurement Value

The first is the widening gap between procurement volume and total procurement value.

Although the total disclosed procurement value remained broadly unchanged at approximately RMB 258 million, the number of awarded systems increased by nearly 30% compared with the previous year.

As a result, the estimated average procurement price declined substantially—from approximately RMB 8.90 million per system in H1 2025 to RMB 6.98 million per system in H1 2026, representing a 21.6% year-over-year decrease.

The decline in average procurement prices reflects the combined effects of intensifying market competition and the accelerating adoption of orthopedic robotic technology across Chinese hospitals.

• Increasing Number of Market Participants

The second notable trend is the continued expansion of supplier participation.

A total of 16 manufacturers secured publicly disclosed procurement awards during the reporting period, compared with 11 manufacturers in the first half of 2025.

The growing number of participating companies highlights increasing commercial activity within China's orthopedic surgical robotics sector and provides important context for understanding the changing competitive landscape discussed later in this report.

Table 2. Orthopedic Surgical Robot Procurement by Manufacturer in H1 2026

Notes:

● Average selling prices are calculated only from procurement projects with publicly disclosed contract values.

● Total procurement values include only projects where financial information was publicly available.

●Longwood Valley MedTech recorded three leasing projects during the reporting period. The reported per-unit values represent leasing contract values rather than capital equipment purchase prices and therefore should not be directly compared with procurement prices of purchased systems.

02 Brand Landscape:

TINAVI Medical Maintains Leadership While Tuodao Medical Doubles Procurement Volume to Become the Second-Largest Domestic Supplier

Among the 16 manufacturers that secured publicly disclosed procurement awards during the first half of 2026, five companies recorded three or more awarded systems, while the remaining 11 manufacturers secured one or two systems each.

In terms of procurement volume, TINAVI Medical ranked first with 15 awarded systems, followed by Tuodao Medical with six systems. Jianjia Robot, Yuanhua Robotics, and Longwood Valley MedTech each secured three systems, while all remaining manufacturers recorded two or fewer awards, illustrating a clear gap between the leading suppliers and the rest of the market.

TINAVI Medical maintained its market-leading position with 15 awarded systems, matching its procurement volume from the first half of 2025. Although its leadership remained intact, the company's market share was passively diluted as the overall market expanded and more manufacturers entered the competitive landscape.

Among the new entrants, Longwood Valley MedTech attracted particular attention. The company secured three procurement awards in its first appearance within the publicly disclosed procurement dataset. Notably, all three projects were leasing contracts rather than outright equipment purchases, making their commercial characteristics fundamentally different from conventional capital procurement.

The most significant competitive shift during the reporting period came from Tuodao Medical.

The company secured six awarded systems in the first half of 2026, doubling its procurement volume from three systems during the same period in 2025. This performance established Tuodao Medical as the second-largest domestic supplier by procurement volume, behind only TINAVI Medical, while creating a clear lead over the third-ranked competitor.

Table 3. Procurement Volume of Major Domestic Manufacturers Across Different Periods

Note: Full-year 2025 data are based on MedRobot's annual analysis of publicly disclosed procurement awards.

Looking at a longer time horizon, Tuodao Medical's growth trajectory becomes even more apparent.

The company secured:

●3 awarded systems in H1 2025

●6 awarded systems during the whole of 2025

●6 awarded systems in H1 2026 alone

In other words, Tuodao Medical matched its entire 2025 procurement volume within just the first six months of 2026.

Growing from three systems to six, and reaching its previous full-year total halfway through the year, the company has demonstrated one of the strongest growth trajectories among China's orthopedic surgical robot manufacturers.

Its geographic footprint also continued to broaden.

The six awarded systems were distributed across Shandong, Shaanxi, Zhejiang and Guangdong provinces, spanning East China, Northwest China and South China, without relying on a single regional market.

From a product perspective, the procurement results suggest that Tuodao Medical's multi-platform orthopedic robotics portfolio is progressing toward broader commercial adoption.

Among the five projects with publicly disclosed contract values, the company's average procurement price was approximately RMB 8.5 million per system, placing it among the higher-priced domestic suppliers.

Taken together, its ability to secure procurement awards across multiple regions, multiple hospital systems and multiple product configurations during the same reporting period indicates that Tuodao Medical has established itself as one of China's leading orthopedic surgical robot companies with nationwide commercial reach.

Competitive Landscape Continues to Differentiate

Overall, the first half of 2026 suggests that China's orthopedic surgical robot market is entering a new stage of competitive development.

While TINAVI Medical continues to maintain a clear leadership position in procurement volume, the gap between the market leader and the second tier is beginning to evolve.

At the same time, a growing number of manufacturers are entering the market, broadening customer choice and intensifying competition.

Rather than a winner-takes-all market, China's orthopedic surgical robotics sector is gradually developing into a multi-tier competitive landscape, characterized by a leading incumbent, a rapidly strengthening second tier, and an expanding group of emerging participants pursuing differentiated commercialization strategies.

03 Pricing and Procurement Models:

Average Procurement Prices Continue to Decline as Leasing Emerges at Scale

During the first half of 2026, the total disclosed procurement value of orthopedic surgical robot projects reached approximately RMB 258 million, broadly unchanged from the same period in 2025. However, the number of awarded systems increased by 10 units, driving a significant decline in the market's average procurement price.

The estimated average procurement price fell from approximately RMB 8.90 million per system in H1 2025 to RMB 6.98 million per system in H1 2026, representing a 21.6% year-over-year decrease.

This trend reflects a market that is moving beyond its early commercialization stage. As competition intensifies and more manufacturers participate in public tenders, pricing has become an increasingly important factor in procurement decisions. At the same time, broader hospital adoption is contributing to a gradual normalization of procurement prices across the market.

Table 4. Average Procurement Price by Manufacturer: H1 2025 vs. H1 2026 (RMB million per system)

Notes:

● Average procurement prices are calculated only from projects with publicly disclosed contract values.

● Manufacturers entering the market during H1 2026 are marked with "—" in the year-over-year comparison because no comparable H1 2025 data are available.

●Longwood Valley MedTech's three projects were all leasing contracts and are therefore excluded from comparisons of capital equipment purchase prices.

Leasing Procurement Makes Its First Meaningful Appearance

Beyond pricing, the first half of 2026 also introduced a notable shift in procurement models.

Leasing-based procurement appeared at meaningful scale for the first time in the publicly disclosed orthopedic surgical robot market.

A total of six leasing projects were identified during the reporting period, involving TINAVI Medical (three systems) and Longwood Valley MedTech (three systems).

All six projects were awarded by leading tertiary hospitals in Beijing:

●Beijing Jishuitan Hospital, Capital Medical University — two leased systems from TINAVI Medical and one from Longwood Valley MedTech

●Beijing Children's Hospital, Capital Medical University — one leased system from TINAVI Medical

●Beijing Friendship Hospital, Capital Medical University — one leased system from Longwood Valley MedTech

●Beijing Anzhen Hospital, Capital Medical University — one leased system from Longwood Valley MedTech

The emergence of leasing introduces a new commercial pathway for orthopedic surgical robotics.

Instead of requiring hospitals to make a substantial upfront capital investment, leasing converts equipment acquisition into periodic operating expenditures, lowering the initial financial threshold for adopting robotic technology.

Interestingly, all identified leasing projects were concentrated within Beijing's leading tertiary hospitals.

Given that these institutions generally possess strong capital budgets and purchasing capabilities, their adoption of leasing arrangements is more likely to reflect a preference for greater procurement flexibility and optimized capital allocation, rather than financial constraints.

This suggests that leasing may increasingly be viewed as a strategic procurement option rather than simply an alternative financing mechanism.

Leasing Values Should Not Be Compared Directly with Purchase Prices

The disclosed contract values further illustrate the structural differences between leasing and conventional procurement.

For TINAVI Medical, the reported leasing contract values were equivalent to approximately RMB 2.33 million to RMB 4.08 million per system, depending on contract duration and structure.

For Longwood Valley MedTech, the corresponding figures ranged from approximately RMB 1.65 million to RMB 3.66 million per system.

Because these figures represent leasing contract values rather than capital equipment purchase prices, they should not be compared directly with average procurement prices reported for purchased systems.

Differences in contract duration, service coverage, maintenance responsibilities and payment structures mean that leasing and outright procurement represent fundamentally different commercial models.

A New Variable in China's Orthopedic Robotics Market

The emergence of leasing-based procurement introduces a new variable into the commercialization of orthopedic surgical robotics in China.

If adopted more broadly by additional hospitals and manufacturers, leasing could influence not only hospitals' purchasing decisions but also future interpretations of procurement statistics, market size estimates and competitive positioning.

Whether this procurement model expands beyond Beijing's leading tertiary hospitals—and whether additional manufacturers incorporate leasing into their commercialization strategies—will be an important trend to monitor in the coming reporting periods.

04 Hospital Adoption:

Tertiary Hospitals Continue to Dominate While Geographic Coverage Expands

During the first half of 2026, procurement of orthopedic surgical robots remained highly concentrated among Class III hospitals, particularly provincial- and municipal-level tertiary general hospitals. Publicly disclosed procurement records indicate that hospitals below the tertiary level accounted for little to no procurement activity during the reporting period.

This concentration reflects the current stage of orthopedic robotic surgery adoption in China. Successful implementation of robotic-assisted orthopedic procedures requires not only advanced surgical equipment but also sufficient procedural volume, well-established surgeon training programs, multidisciplinary clinical coordination and comprehensive perioperative management capabilities. As a result, tertiary hospitals with mature orthopedic programs continue to represent the primary setting for the deployment and routine clinical use of orthopedic surgical robots.

Geographic Expansion Continues

From a regional perspective, the geographic footprint of orthopedic surgical robot procurement broadened further during the first half of 2026.

Compared with the same period in 2025, publicly disclosed procurement projects covered a wider range of provinces across East China, North China, Central China, Southwest China, Northwest China and South China, indicating a more balanced nationwide distribution.

The procurement activities of leading manufacturers were likewise spread across multiple regions, with no clear dependence on a single geographic market. This broader regional distribution suggests that commercialization efforts are gradually extending beyond early-adopting markets and into a wider range of healthcare systems across China.

Tuodao Medical Illustrates Expanding Nationwide Commercialization

Tuodao Medical provides a representative example of this broader trend.

The company's six awarded systems were distributed across Shandong, Shaanxi, Zhejiang and Guangdong provinces, covering East China, Northwest China and South China.

These procurement awards involved both provincial tertiary general hospitals and municipal tertiary hospitals, demonstrating the company's ability to serve healthcare institutions across different administrative levels while expanding its presence in multiple regional markets.

Taken together, Tuodao Medical's procurement performance during the reporting period reflects not only increasing sales volume, but also growing nationwide commercialization capabilities supported by broader geographic penetration and diversified hospital adoption.

Conclusion

China's orthopedic surgical robot market continued to expand during the first half of 2026, with 44 publicly disclosed procurement awards involving 16 manufacturers.

Beyond the increase in procurement volume, the data point to a more meaningful structural shift in the competitive landscape.

TINAVI Medical maintained its leadership position by matching its procurement volume from the previous year, while Tuodao Medical doubled its awarded systems to establish itself as the second-largest domestic supplier by procurement volume. At the same time, the first large-scale adoption of leasing-based procurement among leading tertiary hospitals in Beijing suggests that new commercialization models are beginning to emerge alongside traditional capital equipment purchases.

Looking ahead, competition in China's orthopedic surgical robotics market is likely to extend beyond procurement volume alone.

As the installed base continues to grow and early-adopting hospitals gradually reach saturation, manufacturers will increasingly compete on their ability to build sustainable clinical adoption, strengthen regional penetration and demonstrate long-term commercial execution.

Public procurement data provide only a snapshot of this evolving market. The procurement results in the second half of 2026 will offer further insight into whether the current competitive trends—including vendor differentiation, pricing dynamics and the expansion of leasing models—continue to reshape China's orthopedic surgical robotics landscape.